Suppr超能文献

酒精性肝病中的移植后恶性肿瘤

Post-transplant malignancies in alcoholic liver disease.

作者信息

Singh Akash, De Arka, Singh Virendra

机构信息

Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

出版信息

Transl Gastroenterol Hepatol. 2020 Apr 5;5:30. doi: 10.21037/tgh.2019.11.18. eCollection 2020.

Abstract

Post-transplant malignancy is emerging as an important cause of mortality in patients with cirrhosis undergoing liver transplant (LT). However, establishing the exact relationship between the two needs further evaluation. It has been observed that approximately 30% deaths after 10 years of hepatic transplantation occur due to de novo malignancies. Various known risk factors include immunosuppression, age of patient, alcoholic liver disease (ALD) or primary sclerosing cholangitis, smoking, and oncogenic viral infections. There is scanty literature on the post-transplant malignancy risk in patients with alcoholic cirrhosis. The current evidence suggests a particularly increased risk of oropharyngeal and lung cancers in patients transplanted for ALD. Abstinence from alcohol, smoking and other tobacco-containing products along with optimization of immunosuppression are paramount for decreasing the risk of post-transplant malignancies.

摘要

移植后恶性肿瘤正逐渐成为接受肝移植(LT)的肝硬化患者死亡的重要原因。然而,确定两者之间的确切关系需要进一步评估。据观察,肝移植10年后约30%的死亡是由新发恶性肿瘤所致。各种已知的风险因素包括免疫抑制、患者年龄、酒精性肝病(ALD)或原发性硬化性胆管炎、吸烟和致癌病毒感染。关于酒精性肝硬化患者移植后发生恶性肿瘤的风险,相关文献较少。目前的证据表明,因ALD接受移植的患者发生口咽癌和肺癌的风险尤其增加。戒酒、戒烟和其他含烟草产品,同时优化免疫抑制,对于降低移植后恶性肿瘤的风险至关重要。

相似文献

1
Post-transplant malignancies in alcoholic liver disease.
Transl Gastroenterol Hepatol. 2020 Apr 5;5:30. doi: 10.21037/tgh.2019.11.18. eCollection 2020.
2
Incidence, risk factors and outcomes of de novo malignancies post liver transplantation.
World J Hepatol. 2016 Apr 28;8(12):533-44. doi: 10.4254/wjh.v8.i12.533.
3
Burden of de novo malignancy in the liver transplant recipient.
Liver Transpl. 2012 Nov;18(11):1277-89. doi: 10.1002/lt.23531. Epub 2012 Sep 26.
4
Liver transplantation and alcoholic liver disease: History, controversies, and considerations.
World J Gastroenterol. 2018 Jul 14;24(26):2785-2805. doi: 10.3748/wjg.v24.i26.2785.
5
Immunosuppressive regimen and risk for de novo malignancies after liver transplantation for alcoholic liver disease.
Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):427-435. doi: 10.1016/j.clinre.2018.04.011. Epub 2018 May 31.
6
Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review.
Liver Int. 2010 Oct;30(9):1247-58. doi: 10.1111/j.1478-3231.2010.02303.x.
7
Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis.
Transplantation. 1999 Feb 15;67(3):418-21. doi: 10.1097/00007890-199902150-00014.
9
Risk factors and outcomes associated with alcohol relapse after liver transplantation.
World J Hepatol. 2017 Jun 18;9(17):771-780. doi: 10.4254/wjh.v9.i17.771.
10
malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.
World J Gastroenterol. 2019 Sep 21;25(35):5356-5375. doi: 10.3748/wjg.v25.i35.5356.

引用本文的文献

1
Incidence, screening, and management of malignancies in liver transplant patients: A review.
World J Transplant. 2025 Sep 18;15(3):101046. doi: 10.5500/wjt.v15.i3.101046.
2
Dental and ENT Evaluation Before Liver Transplantation.
J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101431. doi: 10.1016/j.jceh.2024.101431. Epub 2024 Apr 18.
3
Liver transplantation in patients with non-alcoholic steatohepatitis and alcohol-related liver disease: the dust is yet to settle.
Transl Gastroenterol Hepatol. 2022 Jul 25;7:23. doi: 10.21037/tgh-2020-15. eCollection 2022.

本文引用的文献

3
Liver transplantation for alcoholic liver disease.
Nat Rev Gastroenterol Hepatol. 2014 May;11(5):300-7. doi: 10.1038/nrgastro.2013.247. Epub 2014 Jan 7.
4
Lung cancer screening with low-radiation dose computed tomography after liver transplantation.
Ann Transplant. 2013 Oct 29;18:587-92. doi: 10.12659/AOT.884021.
6
Complications in patients with alcohol-associated liver disease who undergo liver transplantation.
Clin Liver Dis. 2012 Nov;16(4):865-75. doi: 10.1016/j.cld.2012.08.013.
7
Burden of de novo malignancy in the liver transplant recipient.
Liver Transpl. 2012 Nov;18(11):1277-89. doi: 10.1002/lt.23531. Epub 2012 Sep 26.
8
Spectrum of cancer risk among US solid organ transplant recipients.
JAMA. 2011 Nov 2;306(17):1891-901. doi: 10.1001/jama.2011.1592.
9
Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
Leuk Lymphoma. 2011 Jun;52(6):950-61. doi: 10.3109/10428194.2011.557453. Epub 2011 Feb 21.
10
Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit.
Am J Transplant. 2010 Aug;10(8):1889-96. doi: 10.1111/j.1600-6143.2010.03181.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验